Chinese biotherapeutics platform Hangzhou Just Biotherapeutics (HJB), which counts Singapore’s Temasek Holdings among its investors, and Sequoia Capital China portfolio firm MabSpace Biosciences (MabSpace) have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a biotherapeutics company, according to a statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
